Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ischemic Heart Disease

  Free Subscription

Articles published in
Lancet
    August 2017
  1. DEHGHAN M, Mente A, Zhang X, Swaminathan S, et al
    Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study.
    Lancet. 2017 Aug 28. pii: S0140-6736(17)32252.
    >> Share

  2. MILLER V, Mente A, Dehghan M, Rangarajan S, et al
    Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study.
    Lancet. 2017 Aug 28. pii: S0140-6736(17)32253.
    >> Share

  3. SIBBING D, Aradi D, Jacobshagen C, Gross L, et al
    Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32155.
    >> Share

  4. KANDZARI DE, Mauri L, Koolen JJ, Massaro JM, et al
    Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32249.
    >> Share

  5. JINATONGTHAI P, Kongwatcharapong J, Foo CY, Phrommintikul A, et al
    Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
    Lancet. 2017;390:747-759.
    >> Share

  6. CUISSET T, Verheugt FWA, Mauri L
    Update on antithrombotic therapy after percutaneous coronary revascularisation.
    Lancet. 2017;390:810-820.
    >> Share

  7. MINTZ GS, Guagliumi G
    Intravascular imaging in coronary artery disease.
    Lancet. 2017;390:793-809.
    >> Share

  8. THE LANCET
    40 years of percutaneous coronary intervention: where next?
    Lancet. 2017;390:715.
    >> Share

  9. DAMMAN P, de Winter RJ
    Timing of revascularisation for acute coronary syndrome.
    Lancet. 2017 Aug 1. pii: S0140-6736(17)31632.
    >> Share

  10. JOBS A, Mehta SR, Montalescot G, Vicaut E, et al
    Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials.
    Lancet. 2017 Aug 1. pii: S0140-6736(17)31490.
    >> Share

    July 2017
  11. ALI ZA, Serruys PW, Kimura T, Gao R, et al
    2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Lancet. 2017 Jul 18. pii: S0140-6736(17)31470.
    >> Share

    May 2017
  12. RUTTY GN, Morgan B, Robinson C, Raj V, et al
    Diagnostic accuracy of post-mortem CT with targeted coronary angiography versus autopsy for coroner-requested post-mortem investigations: a prospective, masked, comparison study.
    Lancet. 2017 May 24. pii: S0140-6736(17)30333.
    >> Share

    April 2017
  13. KOOPMAN JJE, Kuipers RS
    From arterial ageing to cardiovascular disease.
    Lancet. 2017;389:1676-1678.
    >> Share

  14. KAHAN T
    Target blood pressure in patients at high cardiovascular risk.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30935.
    >> Share

  15. BOHM M, Schumacher H, Teo KK, Lonn EM, et al
    Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Lancet. 2017 Apr 5. pii: S0140-6736(17)30754.
    >> Share

  16. VIDAL-PETIOT E, Bhatt DL, Fox KM, Steg PG, et al
    Blood pressure and cardiovascular outcomes: a closer look - Authors' reply.
    Lancet. 2017;389:1296-1297.
    >> Share

  17. WALD NJ, Wald DS
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1296.
    >> Share

  18. DOUMAS M, Stavropoulos KV, Boutari C, Imprialos KP, et al
    Blood pressure and cardiovascular outcomes: a closer look.
    Lancet. 2017;389:1295-1296.
    >> Share

    March 2017
  19. SCHOOLING CM
    Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?
    Lancet. 2017 Mar 27. pii: S0140-6736(16)31648.
    >> Share

  20. GURBEL PA, Tantry US
    GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30760.
    >> Share

  21. OHMAN EM, Roe MT, Steg PG, James SK, et al
    Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Lancet. 2017 Mar 17. pii: S0140-6736(17)30751.
    >> Share

  22. KAPLAN H, Thompson RC, Trumble BC, Wann LS, et al
    Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study.
    Lancet. 2017 Mar 16. pii: S0140-6736(17)30752.
    >> Share

  23. THE LANCET
    Polypills: an essential medicine for cardiovascular disease.
    Lancet. 2017;389:984.
    >> Share

  24. HUFFMAN MD, Xavier D, Perel P
    Uses of polypills for cardiovascular disease and evidence to date.
    Lancet. 2017;389:1055-1065.
    >> Share

    January 2017
  25. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    Hypertension control and cardiovascular disease - Authors' reply.
    Lancet. 2017;389:154-155.
    >> Share

  26. JAMES JE
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:154.
    >> Share

  27. MESSERLI FH, Fischer U, Rimoldi SF, Bangalore S, et al
    Hypertension control and cardiovascular disease.
    Lancet. 2017;389:153.
    >> Share

  28. TAWAKOL A, Ishai A, Takx RA, Figueroa AL, et al
    Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study.
    Lancet. 2017 Jan 12. pii: S0140-6736(16)31714.
    >> Share

    November 2016
  29. COLLINS R, Reith C, Emberson J, Armitage J, et al
    Interpretation of the evidence for the efficacy and safety of statin therapy.
    Lancet. 2016;388:2532-2561.
    >> Share

    October 2016
  30. MAKIKALLIO T, Holm NR, Lindsay M, Spence MS, et al
    Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32052.
    >> Share

  31. MACK M, Holmes DR
    Randomised trials in left main disease: a NOBLE effort.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32067.
    >> Share

  32. VON BIRGELEN C, Kok MM, van der Heijden LC, Danse PW, et al
    Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31920.
    >> Share

  33. FINN AV, Virmani R
    Biodegradable polymer drug-eluting stents: non-inferiority waiting for superiority?
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32063.
    >> Share

  34. ALI ZA, Maehara A, Genereux P, Shlofmitz RA, et al
    Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)31922.
    >> Share

  35. SERRUYS PW, Chevalier B, Sotomi Y, Cequier A, et al
    Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Lancet. 2016 Oct 28. pii: S0140-6736(16)32050.
    >> Share

  36. ROSSIGNOL P, Pitt B, Thompson A, Zannad F, et al
    Roadmap for cardiovascular prevention trials in chronic kidney disease.
    Lancet. 2016;388:1964-1966.
    >> Share

  37. GUAN WJ, Zheng XY, Chung KF, Zhong NS, et al
    Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action.
    Lancet. 2016;388:1939-1951.
    >> Share

  38. ISAAZ K, Gerbay A
    Deferred stenting in acute ST elevation myocardial infarction.
    Lancet. 2016;388:1371.
    >> Share

  39. KELBAEK H, Hofsten DE, Engstrom T, Helqvist S, et al
    Deferred stenting in acute ST elevation myocardial infarction - Authors' reply.
    Lancet. 2016;388:1371-1372.
    >> Share

  40. WONG EM, Chair SY, Leung DY, Sit JW, et al
    The effect of an e-health web-based support programme on psychological outcomes and health related quality of life among Chinese patients with coronary heart disease: a parallel-group randomised controlled trial.
    Lancet. 2016;388 Suppl 1:S86.
    >> Share

    September 2016
  41. FEINBERG MW
    No small task: therapeutic targeting of Lp(a) for cardiovascular disease.
    Lancet. 2016 Sep 21. pii: S0140-6736(16)31329.
    >> Share

    August 2016
  42. CAYLA G, Cuisset T, Silvain J, Leclercq F, et al
    Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31323.
    >> Share

  43. VIDAL-PETIOT E, Ford I, Greenlaw N, Ferrari R, et al
    Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31326.
    >> Share

  44. MANCIA G
    Should blood pressure reduction be aggressive in patients with hypertension and coronary artery disease?
    Lancet. 2016 Aug 26. pii: S0140-6736(16)31398.
    >> Share

  45. WEINTRAUB WS
    Invasive management of acute coronary syndromes.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31273.
    >> Share

  46. WALLENTIN L, Lindhagen L, Arnstrom E, Husted S, et al
    Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
    Lancet. 2016 Aug 25. pii: S0140-6736(16)31276.
    >> Share

  47. REED GW, Rossi JE, Cannon CP
    Acute myocardial infarction.
    Lancet. 2016 Aug 5. pii: S0140-6736(16)30677.
    >> Share

    July 2016
  48. SNYDER A
    Philip Majerus.
    Lancet. 2016;388:458.
    >> Share

  49. KAIN K
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:126.
    >> Share

  50. ETTEHAD D, Emdin CA, Kiran A, Rahimi K, et al
    Blood pressure lowering for cardiovascular disease - Authors' reply.
    Lancet. 2016;388:126-7.
    >> Share

  51. O'KEEFFE DT, Maraka S
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    >> Share

  52. SMULDERS YM, Muller M
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125-6.
    >> Share

  53. COLLINS DR, Albasri A, O'Sullivan J, Bobrovitz N, et al
    Blood pressure lowering for cardiovascular disease.
    Lancet. 2016;388:125.
    >> Share

  54. STONE GW, Gao R, Kimura T, Simonton C, et al
    Optimum technique to reduce risk of stent thrombosis - Authors' reply.
    Lancet. 2016;388:127-8.
    >> Share

  55. SHAH R
    Optimum technique to reduce risk of stent thrombosis.
    Lancet. 2016;388:127.
    >> Share

    June 2016
  56. GLADWIN MT
    Cardiovascular complications and risk of death in sickle-cell disease.
    Lancet. 2016;387:2565-74.
    >> Share

  57. TEGN N, Abdelnoor M, Aaberge L, Endresen K, et al
    Invasive strategy in acute coronary syndrome - Authors' reply.
    Lancet. 2016;387:2504.
    >> Share

  58. MATHEW ST, Pakala AV, Thadani U
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503-4.
    >> Share

  59. SHAH R
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503.
    >> Share

  60. TIMMIS A
    Invasive strategy in acute coronary syndrome.
    Lancet. 2016;387:2503.
    >> Share

  61. POVSIC TJ, Zeiher AM
    IxCELL-DCM: rejuvenation for cardiac regenerative therapy?
    Lancet. 2016;387:2362-3.
    >> Share

  62. FUJITA T
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2289.
    >> Share

  63. FORD C, Whitehead SJ, Gama R, Willmer KA, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2289.
    >> Share

  64. SHAH AS, Anand A, Chapman AR, Newby DE, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction - Authors' reply.
    Lancet. 2016;387:2289-91.
    >> Share

  65. BOEDDINGHAUS J, Twerenbold R, Nestelberger T, Wildi K, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2288.
    >> Share

  66. MULLEN L, Chew PG, Frost F, Obafemi T, et al
    Measurement of cardiac troponin for exclusion of myocardial infarction.
    Lancet. 2016;387:2288-9.
    >> Share

  67. DALE A, Slade E, Heneghan C
    Outcomes reporting of the FAME trial.
    Lancet. 2016;387:2292.
    >> Share

    May 2016
  68. LAFONT A, Mennuni MG
    Effect on death of scaffold thrombosis versus stent thrombosis.
    Lancet. 2016;387:2198.
    >> Share

  69. KAUFMAN JD, Adar SD, Barr RG, Budoff M, et al
    Association between air pollution and coronary artery calcification within six metropolitan areas in the USA (the Multi-Ethnic Study of Atherosclerosis and Air Pollution): a longitudinal cohort study.
    Lancet. 2016 May 24. pii: S0140-6736(16)00378.
    >> Share

  70. MENTE A, O'Donnell M, Rangarajan S, Dagenais G, et al
    Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies.
    Lancet. 2016 May 20. pii: S0140-6736(16)30467.
    >> Share

  71. SABATE M, Brugaletta S
    Outcomes in the EXAMINATION trial - Authors' reply.
    Lancet. 2016;387:1998.
    >> Share

  72. DRYSDALE H, Hartley P, Goldacre B
    Outcomes in the EXAMINATION trial.
    Lancet. 2016;387:1997-8.
    >> Share

  73. CASSESE S, Kastrati A
    Risk of stent thrombosis with bioresorbable vascular scaffolds - Authors' reply.
    Lancet. 2016;387:1904.
    >> Share

  74. SHAH R, Ramos-Bondy B, Mizeracki A
    Risk of stent thrombosis with bioresorbable vascular scaffolds.
    Lancet. 2016;387:1903.
    >> Share

    April 2016
  75. VESTBO J, Anderson JA, Brook RD, Calverley PM, et al
    Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Lancet. 2016;387:1817-1826.
    >> Share

  76. VAN 'T HOF AW, Ottervanger JP
    Primary angioplasty for STEMI: hard to improve upon.
    Lancet. 2016 Apr 1. pii: S0140-6736(16)30123.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016